502 results on '"Concin, Nicole"'
Search Results
2. Evidence for an accumulation of mineral oil saturated hydrocarbons (MOSH) in human tissues: a re-evaluation of biopsy and autopsy data
3. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
4. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium
5. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution
6. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
7. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
8. Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study
9. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
10. Quality Indicators for Ovarian Cancer Surgery
11. Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
12. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
13. Uterine serous carcinoma
14. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
15. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium.
16. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)‐induced phenotypes for platinum sensitivity and long‐term survival in ovarian cancer—A study from the OVCAD consortium.
17. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
18. ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers
19. Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation
20. TP008/#1500 Trial in progress: phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer who responded to chemotherapy (ENGOT-EN21; GOG-3089)
21. Gestational choriocarcinoma
22. #84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)
23. #809 Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients– an international pooled analysis of three ESGO accredited centers
24. #450 Surgical management of malignant intestinal obstruction in patients with ovarian cancer – ten-year experience of a tertiary gynecologic oncology department
25. #644 Surgical management of FIGO stage IV epithelial ovarian cancer versus FIGO stage IIIC: the real-world experience from KEM
26. 60-jährige Patientin mit fortgeschrittenem Ovarialkarzinom: Vorbereitung auf die Facharztprüfung: Fall 4
27. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma
28. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
29. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al
30. The genetic landscape of 87 ovarian germ cell tumors
31. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study
32. Response: FIGO staging of endometrial cancer 2023.
33. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors
34. Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients– A study of the OVCAD consortium
35. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium
36. Prognostic factors in patients with uterine sarcoma: the SARCUT study
37. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients
38. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
39. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
40. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
41. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
42. Supplementary Figure 1 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer
43. Supplementary Figure 2 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer
44. Data from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer
45. Data from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
46. Supplementary Table 1 from Prospective Study of the Association of Serum γ-Glutamyltransferase with Cervical Intraepithelial Neoplasia III and Invasive Cervical Cancer
47. Supplementary Figure 3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer
48. Supplementary Tables 1-3, Figure Legends 1-3 from E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer
49. Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.
50. FIGO staging of endometrial cancer: 2023.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.